Publications by authors named "Mats Anden"

Claim this Profile
P
Prognostic Value of the Circulating Tumor DNA Fraction in Metastatic Castration-resistant Prostate Cancer: Results from the ProBio Platform Trial.
Alessio Crippa, Bram De Laere, Andrea Discacciati, Berit Larsson, Maria Persson, Mats Anden

Eur Urol Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Androgen receptor pathway inhibitors and taxanes in metastatic prostate cancer: an outcome-adaptive randomized platform trial.
Bram De Laere, Alessio Crippa, Andrea Discacciati, Berit Larsson, Maria Persson, Mats Anden

Nat Med· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Author Correction: Androgen receptor pathway inhibitors and taxanes in metastatic prostate cancer: an outcome-adaptive randomized platform trial.
Bram De Laere, Alessio Crippa, Andrea Discacciati, Berit Larsson, Maria Persson, Mats Anden

Nat Med· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Is ultra-hypo-fractionated radiotherapy more cost-effective relative to conventional fractionation in treatment of prostate cancer? A cost-utility analysis alongside a randomized HYPO-RT-PC trial.
Sun Sun, Håkan Jonsson, Klas-Göran Salén, Mats Andén, Lars Beckman

Eur J Health Econ· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world evaluation of upfront docetaxel in metastatic castration-sensitive prostate cancer.
Jenny Isaksson, Henrik Green, Dimitrios Papantoniou, Linn Pettersson, Mats Anden

World J Clin Oncol· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis